These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N. Cancer; 1989 Dec 15; 64(12):2448-58. PubMed ID: 2819654 [Abstract] [Full Text] [Related]
7. [Clinical evaluation of M-VAC chemotherapy (methotrexate, vinblastine, adriamycin and cisplatin) for advanced urothelial cancer]. Gohji K, Takenaka A, Goto A, Hara I, Matsumoto O, Kamidono S, Hamami G, Itani A, Harada K, Tadera N. Nihon Hinyokika Gakkai Zasshi; 1989 Mar 15; 80(3):321-8. PubMed ID: 2659869 [Abstract] [Full Text] [Related]
10. The effect of dose intensity on M-VAC therapy for advanced urothelial cancer. Miyanaga N, Akaza H, Shimazui T, Ohtani M, Koiso K. Cancer Chemother Pharmacol; 1994 Mar 15; 35 Suppl():S5-8. PubMed ID: 7527735 [Abstract] [Full Text] [Related]
11. Chemotherapy of urothelial tract tumors. Yagoda A. Cancer; 1987 Aug 01; 60(3 Suppl):574-85. PubMed ID: 3297286 [Abstract] [Full Text] [Related]
12. [Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer]. Nishio Y, Shirahase T, Shichiri Y, Habuchi T, Matsuda T, Nishimura K, Hida S, Okada Y, Yoshida O. Hinyokika Kiyo; 1988 Aug 01; 34(8):1371-5. PubMed ID: 3195405 [Abstract] [Full Text] [Related]
13. [Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) chemotherapy for advanced urothelial cancers]. Takenaka A, Gotoh A, Hara I, Gohji K, Ogawa T, Arakawa S, Matsumoto O, Kamidono S, Hamami G, Itani A. Gan To Kagaku Ryoho; 1990 Sep 01; 17(9):1909-15. PubMed ID: 2393308 [Abstract] [Full Text] [Related]
14. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced urothelial cancer. Ueki O, Hisazumi H, Uchibayashi T, Naito K, Tajiri S, Takemae K, Kawaguchi K, Kameda K, Nishino A, Nango C. Cancer Chemother Pharmacol; 1992 Sep 01; 30 Suppl():S72-6. PubMed ID: 1394823 [Abstract] [Full Text] [Related]
15. [Primary carcinoma of the female urethra]. Takahashi H, Hirano A, Nakano M, Tanaka K, Shinagawa T. Hinyokika Kiyo; 1989 Nov 01; 35(11):1943-5. PubMed ID: 2618893 [Abstract] [Full Text] [Related]
17. [Methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer--analysis of efficacy and toxicity]. Igawa M, Kadena H, Ohkuchi T, Ueda M, Usui T. Nihon Hinyokika Gakkai Zasshi; 1991 Oct 01; 82(10):1627-36. PubMed ID: 1770701 [Abstract] [Full Text] [Related]
19. [Early clinical result of modified M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for advanced transitional cell carcinoma of renal pelvis and ureter]. Shishido S, Hayakawa M, Higa I, Koyama Y, Hatano T, Osawa A. Hinyokika Kiyo; 1990 Apr 01; 36(4):401-5. PubMed ID: 2378303 [Abstract] [Full Text] [Related]